MapLight Therapeutics, the neurodegenerative biotech that went public this fall, will pay SandboxAQ up to $200 million to discover and develop central nervous system (CNS) disorder treatments.
The big picture: It demonstrates biotech and pharma's growing interest in partnering with AI drug discovery companies to develop new medicines.
